Mohammadreza Rahmani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammadreza Rahmani has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Gervason Moriasi
Department of Medical Biochemistry, School of Medicine, College of Health Sciences Mount Kenya University Thika Kenya
1 shared publicationIbrohim B. Sapaev
Tashkent Institute of Irrigation and Agricultural Mechanization Engineers Tashkent Uzbekistan
1 shared publicationJitendra Gupta
Institute of Pharmaceutical Research GLA University Mathura India
1 shared publicationMarim Alwave
Medical Technical College Al‐Farahidi University Baghdad Iraq
1 shared publicationMaryam Golmohammadi
School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran
1 shared publicationMazin A. A. Najm
Pharmaceutical Chemistry Department, College of Pharmacy Al‐Ayen University Thi‐Qar Iraq
1 shared publication
Latest Publications
- Open Access
- 29 May 2024
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 7 (3) , 195-207
Neuroprotective effects of resveratrol on retinal ganglion cells in glaucoma in rodents: A narrative review
Glaucoma, an irreversible optic neuropathy, primarily affects retinal ganglion cells (RGC) and causes vision loss and blindness. The damage to RGCs in glaucoma occurs by various mechanisms, including elevated intraocular pressure, oxidative stress, inflammation, and other neurodegenerative processes. As the disease progresses, the loss of RGCs leads to vision loss. Therefore, protecting RGCs from damage and promoting their survival are important goals in managing glaucoma. In this regard, resveratrol (RES), a polyphenolic phytoalexin, exerts antioxidant effects and slows down the evolution and progression of glaucoma. The present review shows that RES plays a protective role in RGCs in cases of ischemic injury and hypoxia as well as in ErbB2 protein expression in the retina. Additionally, RES plays protective roles in RGCs by promoting cell growth, reducing apoptosis, and decreasing oxidative stress in H2O2‐exposed RGCs. RES was also found to inhibit oxidative stress damage in RGCs and suppress the activation of mitogen‐activated protein kinase signaling pathways. RES could alleviate retinal function impairment by suppressing the hypoxia‐inducible factor‐1 alpha/vascular endothelial growth factor and p38/p53 axes while stimulating the PI3K/Akt pathway. Therefore, RES might exert potential therapeutic effects for managing glaucoma by protecting RGCs from damage and promoting their survival.
- 29 May 2024
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 7 (3) , 195-207
Open AccessNeuroprotective effects of resveratrol on retinal ganglion cells in glaucoma in rodents: A narrative review
Glaucoma, an irreversible optic neuropathy, primarily affects retinal ganglion cells (RGC) and causes vision loss and blindness. The damage to RGCs in glaucoma occurs by various mechanisms, including elevated intraocular pressure, oxidative stress, inflammation, and other neurodegenerative processes. As the disease progresses, the loss of RGCs leads to vision loss. Therefore, protecting RGCs from damage and promoting their survival are important goals in managing glaucoma. In this regard, resveratrol (RES), a polyphenolic phytoalexin, exerts antioxidant effects and slows down the evolution and progression of glaucoma. The present review shows that RES plays a protective role in RGCs in cases of ischemic injury and hypoxia as well as in ErbB2 protein expression in the retina. Additionally, RES plays protective roles in RGCs by promoting cell growth, reducing apoptosis, and decreasing oxidative stress in H2O2‐exposed RGCs. RES was also found to inhibit oxidative stress damage in RGCs and suppress the activation of mitogen‐activated protein kinase signaling pathways. RES could alleviate retinal function impairment by suppressing the hypoxia‐inducible factor‐1 alpha/vascular endothelial growth factor and p38/p53 axes while stimulating the PI3K/Akt pathway. Therefore, RES might exert potential therapeutic effects for managing glaucoma by protecting RGCs from damage and promoting their survival.